EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India

Abhyuday Saxena, Anupam Prakash

Journal of The Association of Physicians of India · 2026-06 · 74 (6) · 94-96

DOI: 10.59556/japi.74.1507 ↗

At a glance

Übersichtsarbeit in Journal of The Association of Physicians of India, 2026-06. Written by Abhyuday Saxena and 1 co-authors. Institution: Senior Medical Officer, Department of Ophthalmology, Dr. R P Centre, All India Institute of Medical Sciences, New Delhi, India. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides. 34 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin therapies such as tirzepatide have transformed the management of type 2 diabetes mellitus and obesity, with expanding cardiometabolic indications and rapid market growth globally and in India. However, emerging postmarketing evidence has raised concerns regarding ocular safety. Pharmacovigilance analyses, cohort studies, and case reports suggest an association between GLP-1-based therapies and ophthalmic adverse events, including early worsening of diabetic retinopathy and, more concerningly, nonarteritic anterior ischemic optic neuropathy (NAION)-a potentially irreversible cause of sudden vision loss in adults over 50 years. Although the absolute risk appears very low, regulatory agencies, including the WHO and European Medicines Agency, now recognize NAION as a very rare adverse effect of semaglutide, and similar signals are being explored for other agents, suggesting a possible class effect. Proposed mechanisms include altered optic nerve head perfusion, sympathetic-mediated vasoconstriction, and rapid glycemic shifts affecting vascular autoregulation; however, causality remains unproven. In India, where over 100 million adults live with diabetes and obesity rates are rising, even rare adverse events may translate into substantial public health impact, particularly given limited access to ophthalmic care and increasing unsupervised drug use. We advocate a balanced approach: baseline ophthalmic evaluation in high-risk individuals, informed consent regarding visual symptoms, early referral for visual complaints, strengthened pharmacovigilance, and coordinated endocrinology-ophthalmology surveillance systems. As newer triple agonists approach clinical use, integrating ocular safety into prescribing frameworks is imperative. Metabolic gains must not come at the cost of preventable vision loss.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesOptic Neuropathy, IschemicBlindnessHumansIndiaSemaglutideDiabetic Retinopathy

Substances

Hypoglycemic AgentsSemaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptides

Authors and institutions

  • Senior Medical Officer, Department of Ophthalmology, Dr. R P Centre, All India Institute of Medical Sciences, New Delhi, India.
  • Director Professor and Head, Department of Medicine, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India, Corresponding Author.

Cite

APA

Saxena, A., & Prakash, A. (2026). Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India. Journal of The Association of Physicians of India, 74(6), 94-96. https://doi.org/10.59556/japi.74.1507

Vancouver

Saxena A, Prakash A. Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India. Journal of The Association of Physicians of India. 2026;74(6):94-96. doi:10.59556/japi.74.1507

BibTeX
@article{Saxena2026,
  author = {Saxena, Abhyuday and Prakash, Anupam},
  title = {Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India},
  journal = {Journal of The Association of Physicians of India},
  year = {2026},
  volume = {74},
  number = {6},
  pages = {94--96},
  doi = {10.59556/japi.74.1507}
}
Start for free →